Dublin, March 31, 2026 (GLOBE NEWSWIRE) — The “Precision Medicine Software Market Report 2026” has been added to ResearchAndMarkets.com’s offering.
The precision medicine software market is experiencing robust growth, projected to expand from $2.45 billion in 2025 to $2.82 billion in 2026, maintaining a compound annual growth rate (CAGR) of 15.1%. The historic surge can be attributed to advancements in genomic sequencing, increased adoption of electronic health records, and the proliferation of data-driven clinical workflows. The rising focus on oncology-centric precision treatments and the expanded availability of bioinformatics platforms have also played crucial roles.
Looking forward, the market is expected to further escalate to $4.92 billion by 2030, registering a CAGR of 14.9%. This expansion is driven largely by the burgeoning demand for personalized therapeutics, significant investments in precision oncology, and the widespread adoption of AI-powered healthcare analytics and cloud-based platforms. The forecast period will likely witness trends such as AI-driven clinical decision support, integration of genomic and clinical data platforms, and a heightened focus on real-time patient data analytics and interoperable healthcare systems.
Personalized treatment, which involves tailoring medical care based on genetic profiles, lifestyles, and health histories, is set to be a pivotal growth factor. The demand for such targeted treatment strategies is soaring, bolstered by advancements in genomic technologies. In February 2024, the Personalized Medicine Coalition reported a noticeable increase in U.S. FDA approvals for personalized medicines, from 12 in 2022 to 26 in 2023, underscoring this trend.
Key market players are enhancing their digital healthcare solutions to streamline and reduce the costs associated with the creation of digital health products. An example is Huma Therapeutics Ltd., which launched the Huma Cloud Platform in July 2024, facilitating the development of digital-first healthcare applications through AI, with components that integrate seamlessly with medical devices and adhere to major regulatory standards. This platform aims to democratize digital health, supporting proactive AI-driven care and research.
Further expanding its capabilities, QuartzBio, under Precision for Medicine, acquired SolveBio Inc. in January 2023, aiming to fortify its software-as-a-service offerings. This acquisition enhances the management of clinical samples and biomarker data throughout drug development. SolveBio specializes in genomic and clinical data solutions integral to precision medicine.
Prominent companies in this dynamic market include Koninklijke Philips N.V., Palantir Technologies Inc., Tempus Labs Inc., and Foundation Medicine Inc., among others. North America currently leads the market, supported by a strong digital health infrastructure.
Reasons to Purchase:
- Understand the market dynamics with data covering historical trends and future forecasts.
- Identify critical growth segments for investment.
- Leverage forecast data and trend analysis to outpace competitors.
- Conduct in-depth competitor benchmarking based on market share, innovation, and brand strength.
Report Scope:
- By Software Type: CDSS, Genomic Data Tools, Patient Management Software, Bioinformatics Tools
- By Technology: AI, Big Data, Blockchain, IoMT, CRISPR and Gene Editing Tools
- By Deployment: Cloud, On-Premise
- By Application: Oncology, Cardiovascular, CNS, Immunology
- By End User: Healthcare Providers, Research Centers, Pharma and Biotech Companies
The report covers major companies such as Koninklijke Philips N.V., Palantir Technologies Inc., Tempus Labs Inc., and many more. In-depth analysis is available for countries including Australia, Brazil, China, France, Germany, India, and others. Regions covered span across Asia-Pacific, Western Europe, North America, and beyond.
Delivery formats include Word, PDF, or an interactive report coupled with an Excel dashboard for seamless data extraction and analysis. Clients benefit from customization options and expert consulting support.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026-2030 |
| Estimated Market Value (USD) in 2026 | $2.82 Billion |
| Forecasted Market Value (USD) by 2030 | $4.92 Billion |
| Compound Annual Growth Rate | 14.9% |
| Regions Covered | Global |
The companies featured in this Precision Medicine Software market report include:
- Koninklijke Philips N.V.
- Palantir Technologies Inc.
- Tempus Labs Inc.
- Myriad Genetics Inc.
- Foundation Medicine Inc.
- Guardant Health Inc.
- Color Genomics Inc.
- NantHealth Inc.
- SOPHiA GENETICS SA
- Aignostics GmbH
- MVision AI Oy
- Fabric Genomics Inc.
- QUIBIM S.L.
- Syapse Inc.
- PierianDx Inc.
- 2bPrecise LLC
- SimBioSys Inc.
- Navignostics AG
- xCures Inc.
- LifeOmic Holdings LLC
For more information about this report visit https://www.researchandmarkets.com/r/mn8h63
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Precision Medicine Software Market
